How do you approach ILD monitoring when selecting Dato-DXd in frontline TNBC treatment?

ILD rates were very low in TROPION-Breast02, with less than 1% Gr3 or higher. I would follow recommendations per the FDA label and have an awareness of rare potential risk and counsel patients to alert clinical teams should they have symptoms of ILD.

TROP2-directed antibody drug conjugates (ADCs) demonstrate efficacy across various solid tumors. Interstitial lung disease (ILD) represents a significant adverse effect, particularly with ADCs containing the deruxtecan (DXd) payload [1]. Similar to trastuzumab deruxtecan, dato-deruxtecan (Dato-DXd) ...